This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hughes, A. Articles by Calvert, H. Search for Related Content PubMed PubMed Citation Articles by Hughes, A. Articles by Calvert, H. Social Bookmarking                            What's this?

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

From the Department of Medical Oncology, Northern Centre for Cancer Treatment, Newcastle General Hospital, and Cancer Research Unit, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom; and Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.

Address reprint requests to Andy Hughes, MD, PhD, Department of Medical Oncology, Northern Centre for Cancer Treatment, Newcastle General Hospital, Westgate Rd, Newcastle Upon Tyne NE4 6BE, United Kingdom; email: andrew.hughes{at}newcastle.ac.uk

PURPOSE: To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to explore its efficacy. We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural mesothelioma (MPM). The pharmacokinetics of both agents was investigated.

PATIENTS AND METHODS: Twenty-seven patients (23 male, four female) with MPM were treated on five escalating dose levels. Doses ranged from pemetrexed 400 mg/m² (as a 10-minute intravenous infusion), followed by carboplatin area under the plasma concentration-time curve (AUC) 4 mg/mL·min (as a 30-minute intravenous infusion) to pemetrexed 500 mg/m², carboplatin AUC 6 mg/mL·min. All patients had a World Health Organization performance status of 1. A total of 163 courses of treatment were administered (median, six; range, one to 10).

RESULTS: The main toxicity was hematologic, particularly neutropenia, although this was characteristically short-lived and caused few clinical problems. The MTD was pemetrexed 500 mg/m², carboplatin AUC 6, because three of the five patients treated at this dose level experienced a dose-limiting toxicity. Eight partial responses (in 25 assessable patients) were observed for a response rate of 32%. Seventy percent of patients noticed an improvement in symptoms, usually (84%) after only two courses. Median time to progression was 305 days, and median survival time was 451 days.

CONCLUSION: The MTD was pemetrexed 500 mg/m² and carboplatin AUC 6 mg/mL·min. The recommended phase II dose of the combination is pemetrexed 500 mg/m² and carboplatin AUC 5 mg/mL·min. The combination is both active and well tolerated in MPM and deserves further exploration.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. S. Miller, J. A. Blessing, C. N. Krasner, R. S. Mannel, P. Hanjani, M. L. Pearl, S. E. Waggoner, and C. H. Boardman Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group J. Clin. Oncol., June 1, 2009; 27(16): 2686 - 2691. [Abstract] [Full Text] [PDF]

				L V. Rodrigues, J Raposo, C Mendonca, A Figueiredo, F Barata, M Meruje, and J Pires Pleural effusion: what lies underneath? BMJ Case Reports, May 25, 2009; 2009(may25_1): bcr0920080973 - bcr0920080973. [Abstract] [Full Text]

				U. A. Matulonis, N. S. Horowitz, S. M. Campos, H. Lee, J. Lee, C. N. Krasner, S. Berlin, M. R. Roche, L. R. Duska, L. Pereira, et al. Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer J. Clin. Oncol., December 10, 2008; 26(35): 5761 - 5766. [Abstract] [Full Text] [PDF]

				G. Liu, J. Kolesar, D. G. McNeel, C. Leith, K. Schell, J. Eickhoff, F. Lee, A. Traynor, R. Marnocha, D. Alberti, et al. A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors Clin. Cancer Res., May 1, 2008; 14(9): 2732 - 2739. [Abstract] [Full Text] [PDF]

				B. Castagneto, M. Botta, E. Aitini, F. Spigno, D. Degiovanni, O. Alabiso, M. Serra, A. Muzio, R. Carbone, R. Buosi, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM) Ann. Onc., February 1, 2008; 19(2): 370 - 373. [Abstract] [Full Text] [PDF]

				British Thoracic Society Standards of Care Committ BTS statement on malignant mesothelioma in the UK, 2007 Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19. [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				S. Chattopadhyay, R. G. Moran, and I. D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417. [Abstract] [Full Text] [PDF]

				C. Muller, M. Bruhlmeier, P. A. Schubiger, and R. Schibli Effects of Antifolate Drugs on the Cellular Uptake of Radiofolates In Vitro and In Vivo J. Nucl. Med., December 1, 2006; 47(12): 2057 - 2064. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, P. A. Zucali, A. G. Favaretto, F. Grossi, P. Bidoli, G. Del Conte, A. Ceribelli, A. Bearz, E. Morenghi, R. Cavina, et al. Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma J. Clin. Oncol., March 20, 2006; 24(9): 1443 - 1448. [Abstract] [Full Text] [PDF]

				S. Neragi-Miandoab Multimodality approach in management of malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 14 - 19. [Abstract] [Full Text] [PDF]

				R. Maruyama, F. Shoji, T. Okamoto, T. Miyamoto, T. Miyake, T. Nakamura, J. Ikeda, Y. Aoki, H. Wataya, H. Asoh, et al. Triplet Chemotherapy with Cisplatin, Gemcitabine and Vinorelbine for Malignant Pleural Mesothelioma Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 433 - 438. [Abstract] [Full Text] [PDF]

				K. Puto and J. S Garey Pemetrexed Therapy for Malignant Pleural Mesothelioma Ann. Pharmacother., April 1, 2005; 39(4): 678 - 683. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti, C. Kortsik, G. G. Dark, A. Price, C. Manegold, R. Rosell, M. O'Brien, P. M. Peterson, D. Castellano, G. Selvaggi, et al. Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial Clin. Cancer Res., January 15, 2005; 11(2): 690 - 696. [Abstract] [Full Text] [PDF]

				M. Pistolesi and J. Rusthoven Malignant Pleural Mesothelioma: Update, Current Management, and Newer Therapeutic Strategies Chest, October 1, 2004; 126(4): 1318 - 1329. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti, D.-M. Shin, H. L. Kindler, M. J. Vasconcelles, U. Keppler, C. Manegold, H. Burris, U. Gatzemeier, J. Blatter, J. T. Symanowski, et al. Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma J. Clin. Oncol., April 15, 2003; 21(8): 1556 - 1561. [Abstract] [Full Text] [PDF]

				Y. Wang, R. Zhao, S. Chattopadhyay, and I. D. Goldman A Novel Folate Transport Activity in Human Mesothelioma Cell Lines with High Affinity and Specificity for the New-Generation Antifolate, Pemetrexed Cancer Res., November 15, 2002; 62(22): 6434 - 6437. [Abstract] [Full Text] [PDF]